Interim report Q1/2022: Our financial targets remain in place

Significant events in Q1

Significant events after the quarter

• In March, Enzymatica announced that its mouth spray would be launched in Mexico by its partner Sanofi in 2022. The product will be sold under one of Sanofi’s own brands.

• In April, Enzymatica announced that its mouth spray would be launched in Turkey by its partner Sanofi in 2022. The product will be sold under one of Sanofi’s own brands.

Other events during the quarter

• In January, Enzymatica’s partner STADA took over responsibility in Denmark, Norway and Finland för marketing, sales and distribution av ColdZyme. Moving forward, the ColdZyme brand will be phased out in these three markets and the product will be sold under the ViruProtect® brand.
• In March, Enzymatica was granted a patent in Australia for the cod trypsin that is one of the key components in ColdZyme. The patent is valid until 2036.
• In January 2022, a research group at the University of Innsbruck, Austria, published an article with results showing that ColdZyme® blocks the SARS-CoV-2 virus to prevent it from attaching to human tissue. The study was conducted at the initiative of the researchers and was not funded by Enzymatica.

First quarter

• Net sales reached SEK 4.2 (17.0) million.
• The result for the period was SEK -18.0 million (-8.9).
• Earnings per share, basic and diluted, were SEK -0.12
  (-0.06).
• Cash flow from operating activities for the period totaled SEK -10.2 (1.3) million.